Use of PPAR.gamma. agonists for inhibition of inflammatory cytokine production

• US 5,925,657 A
• Filed: 06/18/1997
• Issued: 07/20/1999
• Est. Priority Date: 06/18/1997
• Status: Expired due to Fees

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Jiang, Chengyu, Seed, Brian
• Primary Examiner(s): MacMillan, Keith D.
• Application Number:
  US08/878,406
• Time in Patent Office: 762 Days
• Field of Search: 514/369, 514/370, 514/340, 514/366, 514/365
• US Class Current: 514/369
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings

Abstract

Disclosed herein are methods for reducing or preventing cytokine production associated with an inflammatory response, involving administering to a mammal a therapeutically-effective amount of a thiazolidinedione PPARγ agonist.

Claims

1. A method for reducing or preventing inflammatory cytokine production associated with rheumatoid arthritis in a mammal, said method comprising administering to said mammal a thiazolidinedione PPARγ

agonist in an amount which is sufficient to produce a 50% inhibition of cytokine production in a mammalian monocyte culture.

8. The method of claim 1, 2, 3, 4, or 5, wherein said thiazolidinedione is troglitazone.

9. The method of claim 1, 2, 3, 4, or 5, wherein said cytokine is TNFα

, IL-1β

, or IL-6.

10. The method of claim 1, 2, 3, 4, or 5, wherein said cytokine is produced by a monocyte.

11. The method of claim 1, 2, 3, 4, or 5, wherein said thiazolidinedione PPARγ

agonist is administered orally.

2. A method for reducing or preventing inflammatory cytokine production associated with inflammatory bowel disease in a mammal, said method comprising administering to said mammal a therapeutically-effective amount of a thiazolidinedione PPARγ

agonist.

12. The method of claim 2, 3, 4, or 5, wherein said thiazolidinedione PPARγ

agonist is administered in an amount which is sufficient to produce a 50% inhibition of cytokine production in a mammalian monocyte culture.

3. A method for reducing or preventing inflammatory cytokine production associated with an immunodeficiency syndrome in a mammal, said method comprising administering to said mammal a therapeutically-effective amount of a thiazolidinedione PPARγ

agonist.

4. A method for reducing or preventing inflammatory cytokine production associated with multiple sclerosis in a mammal, said method comprising administering to said mammal a therapeutically-effective amount of a thiazolidinedione PPARγ

agonist.

5. A method for reducing or preventing inflammatory cytokine production associated with cachexia in a mammal, said method comprising administering to said mammal a therapeutically-effective amount of a thiazolidinedione PPARγ

agonist.

6. The method of claim 5, wherein said cachexia results from a neoplasia.

7. The method of claim 5, wherein said cachexia results from a chronic infectious disease.